PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL

被引：0

作者：

Bergmark, Brian ^{[1
]}

O'Donoghue, Michelle ^{[1
]}

Murphy, Sabina ^{[1
]}

Kuder, Julia ^{[1
]}

Ezhov, Marat V. ^{[1
]}

Ceska, Richard ^{[1
]}

Gouni-Berthold, Ioanna ^{[1
]}

Jensen, Henrik Kjaerulf ^{[1
]}

Tokgozoglu, Sadberk Lale ^{[1
]}

Mach, Francois ^{[1
]}

Huber, Kurt ^{[1
]}

Gaciong, Zbigniew ^{[1
]}

Lewis, Basil S. ^{[1
]}

Schiele, Francois ^{[1
]}

Jukema, Johan Wouter ^{[1
]}

Pedersen, Terje ^{[1
]}

Giugliano, Robert ^{[1
]}

Sabatine, Marc Steven ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

914-08

引用

页码：2112 / 2112

页数：1

共 50 条

[21] Nine paths to PCSK9 inhibition
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 299 - U11
[22] Nine paths to PCSK9 inhibition
Asher Mullard
Nature Reviews Drug Discovery, 2017, 16 : 299 - 301
[23] PCSK9-Hemmung – ein UpdateUpdate on PCSK9 inhibition
Julius L. Katzmann
Florian Custodis
Stephan H. Schirmer
Ulrich Laufs
Herz, 2022, 47 : 196 - 203
[24] High glucose effects on PCSK9 expression in aortic VSMC: role of PCSK9 inhibitors
Barale, C.
Melchionda, E.
Russo, I.
DIABETOLOGIA, 2022, 65 (SUPPL 1) : S421 - S421
[25] PCSK9 inhibition to combat hyperlipidaemia
Kang, Seema
LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 366 - 366
[26] Inhibition of ApoCIII: the next PCSK9?
Moens, Sophie J. Bernelot
van Capelleveen, Julian C.
Stroes, Erik S. G.
CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (06) : 418 - 422
[27] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in aortic stenosis - Is this the light at the end of the tunnel for patients with aortic stenosis?
Agstam, Sourabh
Agarwal, Tushar
Gupta, Anunay
Bansal, Sandeep
INDIAN HEART JOURNAL, 2021, 73 (02) : 249 - 252
[28] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
Katsiki, Niki
Athyros, Vasilios G.
Mikhailidis, Dimitri P.
Mantzoros, Christos
METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 74 : 43 - 46
[29] Loss of function in PCSK9, atherogenic lipoprotein concentrations, and calcific aortic valve stenosis
Perrot, N.
Moschetta, D.
Boekholdt, S. M.
Valerio, V.
Martinsson, A.
Capoulade, R.
Mass, E.
Mathieu, P.
Bosse, Y.
Pibarot, P.
Smith, J. G.
Camera, M.
Theriault, Y.
Poggio, P.
Arsenault, B.
EUROPEAN HEART JOURNAL, 2019, 40 : 2877 - 2877
[30] Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody
Roth, Eli M.
Diller, Philip
FUTURE CARDIOLOGY, 2014, 10 (02) : 183 - 199

← 1 2 3 4 5 →